基于社区参考范围估算多囊卵巢综合征患病率:一项横断面研究
该研究在168名非就医社区女性中,采用社区来源的性激素参考范围和mFG评分,结合最保守的PCOM标准,应用改良NIH、Rotterdam和AE-PCOS标准诊断PCOS。结果显示10.1%符合mNIH标准,18.5%符合mRotterdam标准,17.5%符合AE-PCOS标准,但诊断不确定性仍存在。
要点
- 在非就医社区女性中,应用严格标准后PCOS患病率仍存在差异。
- 高雄激素血症与PCOM共存是mNIH与其他标准差异的主要原因。
- 即使采用严格切点,PCOS诊断仍可能漏诊或过度诊断。
核心结论
- 尽管应用了严格的诊断要素定义,在非就医社区样本中诊断PCOS仍存在不确定性。
研究设计与样本
- 澳大利亚横断面研究,纳入168名18-39岁非就医女性,甲功正常、泌乳素正常、近期未妊娠/哺乳/使用全身激素。
主要发现
- 10.1%符合mNIH标准,18.5%符合mRotterdam标准,17.5%符合AE-PCOS标准。
- 27名月经失调者中8名、31名PCOM者中10名、68名高雄激素血症者中39名无其他PCOS特征。
- 19名高雄激素血症患者中,10名(52.5%)符合mNIH标准,14名(78.9%)符合mRotterdam和AE-PCOS标准。
- 高雄激素血症与PCOM共存解释了mNIH与其他标准间最大差异。
关键数值与推荐
- 采用改良NIH(mNIH)标准需月经失调;mRotterdam标准;AE-PCOS标准需高雄激素血症。
- 应用AE-PCOS学会推荐的生化高雄激素和PCOM改良定义。
临床怎么用
- 在社区人群中应用现有诊断标准诊断PCOS需谨慎,避免过度诊断或漏诊。
局限性
- 临床雄激素化依赖参与者自评,但自评与临床评估相比经验证有效。
- 样本量受严格纳入标准和非就医女性需抽血及盆腔超声的要求限制,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does the application of reference ranges for sex steroids and the modified Ferriman-Gallwey (mFG) scale established in the community from which the study sample was drawn, combined with the most conservative polycystic ovary morphology (PCOM) criteria to the recognised diagnostic criteria for polycystic ovary syndrome (PCOS) improve the certainty of diagnosis of PCOS in non-healthcare-seeking women? SUMMARY ANSWER: Despite application of the stringent definitions of the elements used to diagnose PCOS in a non-healthcare seeking community-based sample, the risk of diagnostic uncertainty remains. WHAT IS KNOWN ALREADY: There is heterogeneity in prevalence estimates for PCOS due, in part, to lack of standardisation of the elements comprising the recognised National Institutes of Health (NIH), Rotterdam and Androgen Excess Society (AE-PCOS) diagnostic criteria. The AE-PCOS Society proposed refinements to the definitions of biochemical androgen excess and PCOM that can now be incorporated into these sets of diagnostic criteria to estimate PCOS prevalence. STUDY DESIGN, SIZE, DURATION: An Australian cross-sectional study of 168 non-healthcare-seeking women. PARTICIPANTS/MATERIALS, SETTING, METHODS: The 168 included women were aged 18-39 years, euthyroid and normoprolactinemic, not recently pregnant, breast feeding or using systemic hormones. Each provided menstrual history and assessment of the mFG, had measurement of sex steroids by liquid chromatography, tandem mass spectrometry, and a pelvic ultrasound. The presence of PCOS was determined using modified (m) NIH, Rotterdam, and AE-PCOS criteria according to AE-PCOS Society recommendations. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, 10.1% of the included participants met the mNIH PCOS criteria, which requires the presence of menstrual dysfunction, while 18.5% met the mRotterdam and 17.5% the AE-PCOS criteria, with the latter requiring hyperandrogenism. Eight of the 27 participants with menstrual dysfunction, 10 of 31 women with PCOM, and 39 of 68 women with hyperandrogenism had no other feature of PCOS. Of the 19 participants with hyperandrogenaemia, 10 met the mNIH criteria (52.5%) and 14 met both the mRotterdam and AE-PCOS criteria (78.9%). Women who had the combination of hyperandrogenism and PCOM explained the greatest discrepancy between the mNIH and the other criteria. LIMITATIONS, REASONS FOR CAUTION: Clinical androgenisation relied on participant self-assessment, which has been shown to be valid when compared with clinician assessment. The sample size was a function of both the strict inclusion criteria and the requirements of non-healthcare-seeking women having a blood draw and pelvic ultrasound which may have introduced a selection bias. WIDER IMPLICATIONS OF THE FINDINGS: Despite applying stringent cut-offs for serum androgens, the mFG scale and the ovarian follicle count, these criteria remain arbitrary. Accordingly, healthy women may be captured by these criteria, and misidentified as having PCOS, while women with the condition may be missed. Consequently, PCOS remains a diagnosis to be made with care. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by the Grollo-Ruzzene Foundation. Dr S.R.D. is an NHMRC Senior Principal Research Fellow (Grant no. 1135843). S.R.D. has been paid for developing and delivering educational presentations for Besins Healthcare, BioFemme and Pfizer Australia, has been on Advisory Boards for Theramex, Abbott Laboratories, Mayne Pharmaceuticals and Roche and a consultant to Lawley Pharmaceuticals and Que Oncology and has received has received institutional grant funding for Que Oncology research; there are no other relationships or activities that could appear to have influenced the submitted work. TRIAL REGISTRATION NUMBER: N/A.
引用
- Skiba MA, Bell RJ, Herbert D, et al. Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study. Hum Reprod. 2021. PMID: 33846715. doi:10.1093/humrep/deab069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。